Clinical trials: Carcinoma, Bronchogenic
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung carcinoma (NSCLC) - stage IIIB/IV.
- Trial name
- iTRAP (NCT03498222)
- Testing
- Atezolizumab, Pemetrexed, Carboplatin
- Sponsor
- Queen Mary University of London
Lung Cancer
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003202
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumors
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer.
- Trial name
- NCT04999202
- Testing
- BAY2416964, Pembrolizumab
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 47 people
- Sponsor
- Bayer
Non-small Cell Lung Cancer
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival…
- Trial name
- STAR-121 (NCT05502237)
- Testing
- Zimberelimab, Domvanalimab, Pembrolizumab
- Where
- 186 sites in United States, Argentina and 21 more
- Volunteers
- 1,021 people
- Sponsor
- Gilead Sciences
Non-small Cell Lung Cancer
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group.
- Trial name
- NCT03150875
- Testing
- IBI308, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 290 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well sorafenib works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00098540
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- XACT-LUNG (NCT02905591)
- Testing
- Radiation Therapy, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Joseph J. Cullen, MD, FACS
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Lung Cancer, NSCLC
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-naïve patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung…
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
- Trial name
- CUBIK (NCT04223596)
- Testing
- Brigatinib
- Where
- 15 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)
The goal of this retrospective study is to identify predictive biomarkers of efficacy in tumor samples of small cell lung cancer patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry.
- Trial name
- HYPE (NCT06558903)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Brest
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma
Celecoxib Treatment for Lung Cancer
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer.
- Trial name
- NCT00108186
- Testing
- Celecoxib
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Metastatic Non-Small-Cell Lung Cancer
Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
The present study has been designed in order to characterize the incidence of patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) positive mutations and their clinical…
- Trial name
- NCT01717105
- Where
- 9 sites in Spain
- Volunteers
- 225 people
- Sponsor
- Grupo Gallego de Cancer de Pulmon
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
To evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- DP-EN-RT (NCT01218594)
- Testing
- Endostatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Breast Cancer
Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy
As cytotoxic agents, DTX and PTX have a narrow therapeutic window. BSA dosing leads to great inter-individual PK variability, which is a major contributor for severe toxicity, especially in East-Asian populations.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Nasal Cancer
- Trial name
- NCT01891123
- Testing
- PK guided arm, PTX 175mg/m2, DOC 75mg/m2
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.